Table 1 Clinical and cytogenetic characteristics of the study cohort
From: Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia
Characteristics | All patients N (%) | TP53MT N (%) | TP53WT N (%) | p-value |
|---|---|---|---|---|
Number of patients | 7400 (100%) | 1010 (14%) | 6390 (86%) | Â |
Median age at diagnosis (IQR) | 70.3 (61–77) | 71 (64–77) | 70 (61–77) | 0.001 |
Male gender (%) | 58% | 53% | 59% | 0.015 |
Disease subtypes | ||||
 pAML | 1985 (26.8%) | 316 (31.2%) | 1669 (26.1%) |  < 0.001 |
 sAML | 272 (3.6%) | 111 (10.9%) | 161 (2.5%) |  < 0.001 |
 HR–MDS | 1273 (17.2%) | 234 (23.1%) | 1038 (16.2%) |  < 0.001 |
 LR–MDS | 2558 (34.6%) | 244 (24.1%) | 2314 (36.3%) |  < 0.001 |
 MDS/MPN | 1312 (17.8%) | 105 (10.4%) | 1208 (18.9%) |  < 0.001 |
Cytogenetic data* | ||||
 Normal | 2084 (47.8%) | 122 (12.4%) | 1967 (58.2%) |  < 0.001 |
 Complex | 1083 (24.8%) | 704 (71.7%) | 344 (10.1%) |  < 0.001 |
 Deletion 5q | 211 (4.8%) | 95 (9.6%) | 116 (3.4%) |  < 0.001 |
 Deletion 7 | 146 (3.3%) | 20 (2.0%) | 126 (3.7%) | 0.009 |
 Deletion 17p | 207 (4.7%) | 167 (17.0%) | 40 (1.1%) |  < 0.001 |
 Deletion 20q | 93 (2.1%) | 8 (0.8%) | 85 (2.5%) | 0.001 |
 Trisomy 8 | 252 (5.7%) | 36 (3.6%) | 216 (6.3%) | 0.001 |
 Deletion Y | 84 (1.9%) | 10 (1.0%) | 74 (2.1%) | 0.018 |
 Median Hb (IQR) | 9.7 (8.5–11.1) | 9.1 (8.2–10.2) | 9.8 (8.6–11.2) |  < 0.001 |
 Median WBC (IQR) | 6.8 (3.3–23.6) | 5.1 (2.6–16.3) | 7.1 (3.4–24.9) |  < 0.001 |
 Median platelet (IQR) | 105 (50–208) | 65 (38–120) | 113 (54–220) |  < 0.001 |